MiNK Therapeutics, Inc. – NASDAQ:INKT
MiNK Therapeutics stock price today
$14.7
+14.12
+2456.52%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
MiNK Therapeutics stock price monthly change
-48.66%
month
MiNK Therapeutics stock price quarterly change
-48.66%
quarter
MiNK Therapeutics stock price yearly change
-44.17%
year
MiNK Therapeutics key metrics
Market Cap | 19.67M |
Enterprise value | N/A |
P/E | -2.5 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | -139.43 |
PEG ratio | -0.36 |
EPS | -0.60 |
Revenue | N/A |
EBITDA | -20.68M |
Income | -20.58M |
Revenue Q/Q | -100% |
Revenue Y/Y | -166.77% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMiNK Therapeutics stock price history
MiNK Therapeutics stock forecast
MiNK Therapeutics financial statements
| Jun 2023 | 0 | -6.19M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.11M | |
| Dec 2023 | -11.70B | -5.45M | 0.05% |
| Mar 2024 | 0 | -3.81M |
| Sep 2025 | 0 | -5.66M | |
|---|---|---|---|
| Oct 2025 | 0 | -4.15M | |
| Dec 2025 | 0 | -7.41M | |
| Dec 2025 | 0 | -5.19M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.18 | -0.15 |
|---|---|---|
| 2024-03-21 | -0.15 | -0.16 |
| Jun 2023 | 12111923 | 21.60M | 178.4% |
|---|---|---|---|
| Sep 2023 | 7461612 | 21.04M | 282.01% |
| Dec 2023 | 4552281 | 22.60M | 496.62% |
| Mar 2024 | 6893943 | 27.19M | 394.45% |
| Jun 2023 | -4.15M | -37.01K | -75.69K |
|---|---|---|---|
| Sep 2023 | -4.20M | -23.04K | 2.95K |
| Dec 2023 | -3.03M | -73.48M | -2 |
| Mar 2024 | -2.54M | 0 | 5.00M |
MiNK Therapeutics alternative data
| Aug 2023 | 37 |
|---|---|
| Sep 2023 | 37 |
| Oct 2023 | 37 |
| Nov 2023 | 37 |
| Dec 2023 | 37 |
| Jan 2024 | 37 |
| Feb 2024 | 37 |
| Mar 2024 | 31 |
| Apr 2024 | 31 |
| May 2024 | 31 |
| Jun 2024 | 31 |
| Jul 2024 | 31 |
MiNK Therapeutics other data
1.55%
-0.38%
of INKT is owned by hedge funds
522.09K
-127.90K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 395788 | 100000 |
| Aug 2023 | 212730 | 0 |
| Oct 2023 | 37976 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 14 May 2023 | Q1 2023 Earnings Call Transcript |
-
What's the price of MiNK Therapeutics stock today?
One share of MiNK Therapeutics stock can currently be purchased for approximately $14.7.
-
When is MiNK Therapeutics's next earnings date?
Unfortunately, MiNK Therapeutics's (INKT) next earnings date is currently unknown.
-
Does MiNK Therapeutics pay dividends?
No, MiNK Therapeutics does not pay dividends.
-
How much money does MiNK Therapeutics make?
MiNK Therapeutics has a market capitalization of 19.67M. MiNK Therapeutics made a loss 22.46M US dollars in net income (profit) last year or -$0.16 on an earnings per share basis.
-
What is MiNK Therapeutics's stock symbol?
MiNK Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "INKT".
-
What is MiNK Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of MiNK Therapeutics?
Shares of MiNK Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does MiNK Therapeutics have?
As Jul 2024, MiNK Therapeutics employs 31 workers.
-
When MiNK Therapeutics went public?
MiNK Therapeutics, Inc. is publicly traded company for more then 3 years since IPO on 15 Oct 2021.
-
What is MiNK Therapeutics's official website?
The official website for MiNK Therapeutics is minktherapeutics.com.
-
Where are MiNK Therapeutics's headquarters?
MiNK Therapeutics is headquartered at 149 Fifth Avenue, New York, NY.
-
How can i contact MiNK Therapeutics?
MiNK Therapeutics's mailing address is 149 Fifth Avenue, New York, NY and company can be reached via phone at +212 9948250.
MiNK Therapeutics company profile:
MiNK Therapeutics, Inc.
minktherapeutics.comExchange:
NASDAQ
Full time employees:
31
Industry:
Biotechnology
Sector:
Healthcare
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
149 Fifth Avenue
New York, NY 10010
New York, NY 10010
CIK: 0001840229
ISIN: US6036931029
CUSIP: 603693102
